Insulet Corp. (PODD) on Decifer

Decifer ranks PODD number 220 of 265 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 14% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 31% a year, profits are expected to grow 19%, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• And it returns cash to shareholders and its own insiders have been buying.
• Revenue growing 31% with 14% returns cannot overcome a 0 out of 35 momentum score and no funded demand wave.

The current read

The evidence on PODD lines up on the supportive side: research view: PODD is a high-conviction name in GLP-1 & Metabolic Health. The independent signals we track are telling the same story.

Themes

• GLP-1 & Metabolic Disease Wave: GLP-1 receptor agonists have demonstrated large-scale efficacy in obesity and diabetes, triggering a multi-hundred-billion-dollar demand and capex surge across pharma and diabetes-device makers.

Read the full PODD research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.